@Article{,
AUTHOR = {Fred Saad},
TITLE = {UPM3: review of a new molecular diagnostic urine test for prostate cancer},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {12},
YEAR = {2005},
NUMBER = {Suppl.1},
PAGES = {40--43},
URL = {http://www.techscience.com/CJU/v12nSuppl.1/63380},
ISSN = {1488-5581},
ABSTRACT = {PSA elevation is the most common indication for urologic
referral to rule out the presence of prostate cancer.
Recently PSA screening and its usefulness in suggesting
the presence of clinically significant prostate cancer has
been put into doubt. PSA has limitations in detecting
significant cancers even when elevated and on the other
hand significant cancers are found in the presence of low
PSA levels. In order to better predict patients at risk of
harboring prostate cancer new diagnostic tests are
required. A promising novel approach is based on the
molecular detection of prostate cancer cells in urine. The
uPM3 assay is based on the amplification of specific target
RNA using the nucleic acid sequence-based amplification
(NASBA) technology. In a large multi-center study of
517 cases the overall sensitivity was 66% with a
specificity of 89%. The positive (PPV) predictive values
for the uPM3 test were 75% compared to 38% for a serum
PSA cutoff of 4. The negative predictive value (NPV)
was equivalent between the tests, but due to the higher
PPV for uPM3, the accuracy of uPM3 was nearly twofold greater than PSA (81% versus 43% and 47% for
PSA cutoffs of 2.5 ng/ml and 4 ng/ml, respectively). This
test may become one of the first molecular diagnostic tools
to aid in prostate cancer detection.},
DOI = {}
}